Novo Nordisk A/S (NVO) vs Sanofi (SNY)
Novo Nordisk A/S and Sanofi are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $129.3B against $97.4B — 1.3× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 21.5×. Sanofi grew revenue faster over the last twelve months: 21.3% against 13.2%. Novo Nordisk A/S has the higher net margin (35.5% vs 8.22%) and the higher return on invested capital (28.7% vs 6.58%). Both pay a dividend; Sanofi yields more (4.40% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 12 and Sanofi on 11.
Valuation
Profitability
| Metric | NVO | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 80.73% | 72.78% | 72.77% |
| Operating margin | 43.36% | 18.24% | 18.90% |
| Net margin | 35.47% | 8.22% | 8.27% |
| Free cash flow margin | 14.79% | 25.53% | 17.25% |
| Return on equity | 60.84% | 5.87% | 6.97% |
| Return on assets | 22.00% | 3.21% | 2.76% |
| Return on invested capital | 28.67% | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack